Share

Artificial Intelligence Improves X-ray Identification of Patients with Broken Bones

Artificial intelligence that can “read” electronic radiology reports and flag patients with broken bones who are at risk of osteoporosis outperformed the traditional manual method of health care professionals reading X-ray reports, a new study finds. The results were presented during a virtual news conference hosted by the Endocrine Society. The new search tool, called...
Share

FDA Approves First Treatment for Thyroid Eye Disease

In January, Endocrine News reported on the possible upcoming availability of teprotumumab as a promising treatment for of thyroid eye disease (TED), a serious, progressive and vision-threatening rare autoimmune disease that is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain, inflammation, and facial disfigurement. Up to 50% of patients with Graves’ disease...
Share

It’s Easy Being Green in the Lab

endogear_touchpad Laboratories are one of the next major frontiers in sustainability. Laboratories consume as much as five times more energy per square foot than typical offices, and the opportunity for energy reduction is enormous. While the combination of energy-intensive equipment, round-the-clock operations, and unique ventilation requirements do pose a challenge when looking at reducing a lab’s...
Share

Rise of the Machines: Artificial Intelligence in Healthcare

Artificial intelligence – once only found in a Steven Spielberg movie – is being adopted by the healthcare industry more and more from improving diabetes outcomes to reducing unnecessary thyroid surgeries. As these technologies improve, clinicians will soon have yet another ally to individualize patient care. Artificial intelligence. Machine learning. Those very phrases stir up...
Share

Positive Top-Line Results Announced from the Pivotal Phase 3 SONICS Study of Levoketoconazole for the Treatment of Endogenous Cushing’s Syndrome

Positive top-line results this week were announced from the multinational, pivotal Phase 3 SONICS study evaluating levoketoconazole for the treatment of endogenous Cushing’s syndrome. Strongbridge Biopharma is marketing the drug as RECORLEV™ . The open-label, single-arm SONICS study achieved statistical significance of its pre-specified primary endpoint, with 30 percent of patients achieving normalization of mean urinary...